Oman Diabetes Drugs and Devices Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Oman Diabetes Drugs and Devices Market is Segmented by Drugs (Insulin, Oral Anti-Diabetic Drugs, Non-Insulin Injectable Drugs, and Combination Drugs), and Devices (Management Devices (Insulin Pumps, Insulin Pens, Syringes, Cartridges, and Jet Injectors) and Monitoring Devices (Self-Monitoring Blood and Continuous Glucose Monitoring)). The Report Offers the Value (In USD) and Volume (In Unit) for the Above Segments.

Oman Diabetes Drugs and Devices Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Oman Diabetes Drugs and Devices Market Size

Oman Diabetes Drugs and Devices Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Historical Data Period 2019 - 2023
Market Size (2025) USD 209.02 Million
Market Size (2030) USD 266.77 Million
CAGR (2025 - 2030) 5.00 %

Major Players

Oman Diabetes Drugs And Devices Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Oman Diabetes Drugs And Devices Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Oman Diabetes Drugs and Devices Market Analysis

The Oman Diabetes Drugs And Devices Market size is estimated at USD 209.02 million in 2025, and is expected to reach USD 266.77 million by 2030, at a CAGR of greater than 5% during the forecast period (2025-2030).

The COVID-19 pandemic has positively impacted the Oman diabetes care equipment market growth. Diabetics infected with SARS-CoV-2 experience additional stress and increased secretion of hyperglycemic hormones, leading to elevated blood sugar levels, abnormal blood sugar fluctuations, and diabetic complications. Diabetes and uncontrolled hyperglycemia are risk factors for poor prognosis in COVID-19 patients, including increased risk of serious illness and death. To avoid complications, the patient's blood glucose level must be normal. Diabetic device makers are scrambling to ship devices to diabetics with the help of local governments during the COVID-19 crisis. The pandemic emergency has increased telemedicine by both patients and healthcare workers, removing many long-standing regulatory barriers.

Diabetes is associated with many health complications. People with diabetes need to make multiple corrections throughout the day to maintain nominal blood sugar levels, such as administering additional insulin or monitoring blood sugar levels and ingesting other carbohydrates.

Diabetes is a growing health burden nationwide and is a leading cause of premature death, morbidity, and loss of economic growth. Oman's Ministry of Health recently attended the virtual launch of the WHO Global Diabetes Compact, co-hosted by the World Health Organization and the Government of Canada. The compact aims to raise awareness of diabetes as a global disease and expand prevention and treatment as part of primary health care. Care and general health care.

Diabetes is an expensive chronic disease that requires medical devices to monitor blood sugar levels, according to the Oman Diabetes Association. This poses a challenge for low-income and social security patients, and efforts are being made to reduce the burden on these patients and promote carbohydrate restriction.

As part of an ODA initiative, Oman is trying to educate people with diabetes on the use of blood glucose meters. In addition, there are about 60 new pediatric infections per year. According to local studies and reports of reasonable diabetes control, the rate is 32-35% in adult patients but reaches 10-12% in children and adolescents. Governments are working to raise awareness of diabetes and increase access to blood glucose meters to improve diabetes management in children.

Based on the abovementioned factors, the market under study is expected to grow during the analysis period.

Oman Diabetes Drugs and Devices Industry Overview

In order to survive in the market, manufacturers have constantly innovated. Large companies like Abbott and Medtronic have made numerous mergers, acquisitions and partnerships to gain market dominance while adhering to organic growth strategies. Manufacturers of insulin dosing devices spend a lot of money on R&D of the drugs and devices.

Oman Diabetes Drugs and Devices Market Leaders

  1. Medtronics

  2. Roche

  3. NovoNordisk

  4. Sanofi

  5. Omnipod

  6. *Disclaimer: Major Players sorted in no particular order
Oman Diabetes Drugs And Devices Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Oman Diabetes Drugs and Devices Market News

  • April 2023: The Ministry of Health Research Centre in Oman has undertaken research to explore various models that aim to enhance the accuracy of T2DM diagnoses for Omani Prediabetes Patients. These models utilize Artificial Neural Networks and Six Machine Learning Classifiers.
  • October 2022: The Ministry of Industry and Advanced Technology announced the signing of a pair of memoranda of understanding worth AED 260 million (USD 70.8 million) between major pharmaceutical and medical device companies in the UAE. The partnerships align with the National Strategy for Industry and Advanced Technology and the ICV Program. It aims to attract investors and manufacturers to the UAE's pharmaceutical and medical equipment sectors. Under a separate MoU, PureHealth, and Gulf Pharmaceutical Industries Company will establish the first factory in the Middle East to produce Glargine to treat diabetes.

Oman Diabetes Drugs and Devices Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Dynamics
    • 4.2.1 Market Drivers
    • 4.2.2 Market Restraints
  • 4.3 Porter's Five Forces Analysis
    • 4.3.1 Bargaining Power of Suppliers
    • 4.3.2 Bargaining Power of Consumers
    • 4.3.3 Threat of New Entrants
    • 4.3.4 Threat of Substitute Products and Services
    • 4.3.5 Intensity of Competitive Rivalry

5. Market Segmentation (Market Size by Value - USD)

  • 5.1 Devices
    • 5.1.1 Monitoring Devices
    • 5.1.1.1 Self-monitoring Blood Glucose Devices
    • 5.1.1.2 Continuous Blood Glucose Monitoring
    • 5.1.2 Management Devices
    • 5.1.2.1 Insulin Pump
    • 5.1.2.2 Insulin Syringes
    • 5.1.2.3 Insulin Cartridges
    • 5.1.2.4 Disposable Pens
  • 5.2 Drugs
    • 5.2.1 Oral Anti-Diabetes Drugs
    • 5.2.2 Insulin Drugs
    • 5.2.3 Combination Drugs
    • 5.2.4 Non-Insulin Injectable Drugs

6. Market Indicators

  • 6.1 Type-1 Diabetes Population
  • 6.2 Type-2 Diabetes Population

7. COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles
    • 7.1.1 Novo Nordisk
    • 7.1.2 Medtronic
    • 7.1.3 Insulet
    • 7.1.4 Tandem
    • 7.1.5 Ypsomed
    • 7.1.6 Novartis
    • 7.1.7 Sanofi
    • 7.1.8 Eli Lilly
    • 7.1.9 Abbottt
    • 7.1.10 Roche
    • 7.1.11 Astrazeneca
    • 7.1.12 Dexcom
    • 7.1.13 Pfizer
  • *List Not Exhaustive
  • 7.2 Company Share Analysis

8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
*Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments.
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Oman Diabetes Drugs and Devices Industry Segmentation

A blood glucose meter (BGM) measures the blood glucose level at the measurement time. To use the meter, a small amount of blood is dripped onto the test strip by inserting the test strip and pricking a finger with a lancing device to obtain a blood sample. The meter displays blood glucose levels in mg/dl (US standard) or mmol/l (European standard). Oman diabetes drugs and devices market is segmented by drugs (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs), and devices (management devices (insulin pumps, insulin pens, syringes, cartridges, and jet injectors) and monitoring devices (self-monitoring blood and continuous glucose monitoring)). The report offers the value (in USD) and volume (in unit) for the above segments.

Devices Monitoring Devices Self-monitoring Blood Glucose Devices
Continuous Blood Glucose Monitoring
Management Devices Insulin Pump
Insulin Syringes
Insulin Cartridges
Disposable Pens
Drugs Oral Anti-Diabetes Drugs
Insulin Drugs
Combination Drugs
Non-Insulin Injectable Drugs
Need A Different Region or Segment?
Customize Now

Oman Diabetes Drugs and Devices Market Research Faqs

How big is the Oman Diabetes Drugs And Devices Market?

The Oman Diabetes Drugs And Devices Market size is expected to reach USD 209.02 million in 2025 and grow at a CAGR of greater than 5% to reach USD 266.77 million by 2030.

What is the current Oman Diabetes Drugs And Devices Market size?

In 2025, the Oman Diabetes Drugs And Devices Market size is expected to reach USD 209.02 million.

Who are the key players in Oman Diabetes Drugs And Devices Market?

Medtronics, Roche, NovoNordisk, Sanofi and Omnipod are the major companies operating in the Oman Diabetes Drugs And Devices Market.

What years does this Oman Diabetes Drugs And Devices Market cover, and what was the market size in 2024?

In 2024, the Oman Diabetes Drugs And Devices Market size was estimated at USD 198.57 million. The report covers the Oman Diabetes Drugs And Devices Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Oman Diabetes Drugs And Devices Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Oman Diabetes Drugs and Devices Industry Report

Statistics for the 2025 Oman Diabetes Drugs And Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Oman Diabetes Drugs And Devices analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.